References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
- Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review. JAMA. 2020;324(19):1980–1991. doi:https://doi.org/10.1001/jama.2020.17598.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Tan WS, Rodney S, Lamb B, et al. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22–31. doi:https://doi.org/10.1016/j.ctrv.2016.05.002.
- Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi:https://doi.org/10.1016/j.eururo.2020.03.055.
- Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Actas Urol Esp. 2012;36(7):389–402. doi:https://doi.org/10.1016/j.acuroe.2011.12.007.
- Lu M, Chen S, Zhou Q, et al. Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): a study based on 477 patients. Medicine 2019;98(28):e16426. doi:https://doi.org/10.1097/MD.0000000000016426.
- Sylvester RJ, Van Der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–465. doi:https://doi.org/10.1016/j.eururo.2005.12.031.
- Bertz S, Otto W, Denzinger S, et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur. Urol. 2014;65(1):218–226. doi:https://doi.org/10.1016/j.eururo.2012.05.033.
- Oderda M, Ricceri F, Pisano F, et al . Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study. Urol Int. 2013;90(2):184–190. doi:https://doi.org/10.1159/000343431.
- Reuter VE, Argani P, Zhou M, et al. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e35–e49. doi:https://doi.org/10.1097/PAS.0000000000000258.
- Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder rumours. Eur Urol. 2016;70(1):106–119. doi:https://doi.org/10.1016/j.eururo.2016.02.028.
- Casey RG, Catto JW, Cheng L, et al. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015;67(5):876–888. doi:https://doi.org/10.1016/j.eururo.2014.10.040.
- Babjuk M, Burger M, Comperat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 update. Eur Urol. 2019;76(5):639–657. doi:https://doi.org/10.1016/j.eururo.2019.08.016.
- Cambier S, Sylvester RJ, Collette L, et al . EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus calmette-guérin. Eur Urol. 2016;69(1):60–69. doi:https://doi.org/10.1016/j.eururo.2015.06.045.
- Jiang P, Jia M, Hu J, et al. A nomogram model involving immunohistochemical markers for predicting the recurrence of stage I-II endometrial cancer. Front Oncol. 2021;10:586081. doi:https://doi.org/10.3389/fonc.2020.586081.
- Van Rhijn BW, Liu L, Vis AN, et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int. 2012;110(8):1169–1176. doi:https://doi.org/10.1111/j.1464-410X.2012.10996.x.
- Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–5951. doi:https://doi.org/10.1200/JCO.2008.19.6147.
- Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011;71(17):5601–5605. doi:https://doi.org/10.1158/0008-5472.CAN-11-1316.
- Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–618. doi:https://doi.org/10.1200/JCO.2010.30.5425.
- Oddens JR, Van Der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol. 2004;46(3):336–338.
- Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604. doi:https://doi.org/10.1093/jnci/93.8.597.
- Faba OR, Breda A, Palou J. Re: value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol. 2018;74(3):397–398. doi:https://doi.org/10.1016/j.eururo.2018.03.025.
- Messing EM, Tangen CM, Lerner SP, et al. Effect of intravesical instillation of gemcitabine vs. saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA. 2018;319(18):1880–1888. doi:https://doi.org/10.1001/jama.2018.4657.
- Dalkilic A, Bayar G, Kilinc MF. A comparison of EORTC and CUETO risk tables in terms of the prediction of recurrence and progression in all non-muscle-invasive bladder cancer patients. Urol J. 2019;16(1):37–43.
- Taylor J, Becher E, Steinberg GD. Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2020;125(2):197–205. doi:https://doi.org/10.1111/bju.14915.
- Van Rhijn BW, Van Der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU International. 2009;106(2):206–211. doi:https://doi.org/10.1111/j.1464-410X.2009.09100.x.
- Shire Z, Vakili MR, Morgan TDR, et al. Nanoencapsulation of novel inhibitors of PNKP for selective sensitization to ionizing radiation and irinotecan and induction of synthetic lethality. Mol Pharm. 2018;15(6):2316–2326. doi:https://doi.org/10.1021/acs.molpharmaceut.8b00169.
- Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology. 2005;66(1):64–74. doi:https://doi.org/10.1016/j.urology.2005.08.065.